Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/29626
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSayan, Murat-
dc.contributor.authorSargın, Fatma-
dc.contributor.authorİnan, Dilara-
dc.contributor.authorSevgi, Dilek Y.-
dc.contributor.authorÇelikbaş, Aysel K.-
dc.contributor.authorYaşar, Kadriye-
dc.contributor.authorKaptan, Figen-
dc.contributor.authorKutlu, Selda-
dc.contributor.authorFışgın, Nuriye T.-
dc.contributor.authorİnci, Ayşe-
dc.contributor.authorCeran, Nurgül-
dc.contributor.authorKaraoğlan, İlkay-
dc.contributor.authorÇağatay, Atahan-
dc.contributor.authorÇelen, Mustafa K.-
dc.contributor.authorKoruk, Suda T.-
dc.contributor.authorCeylan, Bahadir-
dc.contributor.authorYıldırmak, Taner-
dc.contributor.authorKorten, Volkan-
dc.contributor.authorWillke, Ayşe-
dc.date.accessioned2022-11-29T11:23:23Z-
dc.date.available2022-11-29T11:23:23Z-
dc.date.issued2016-01-01-
dc.identifier.citationSayan, M. vd. (2016). "HIV-1 transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in Turkey". AIDS Research and Human Retroviruses, 32(1), 26-31.en_US
dc.identifier.issn0889-2229-
dc.identifier.issn1931-8405-
dc.identifier.urihttps://doi.org/10.1089/aid.2015.0110-
dc.identifier.urihttps://www.liebertpub.com/doi/10.1089/aid.2015.0110-
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692107/-
dc.identifier.urihttp://hdl.handle.net/11452/29626-
dc.description.abstractHIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts.en_US
dc.language.isoenen_US
dc.publisherMary Ann Lieberten_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectImmunologyen_US
dc.subjectInfectious diseasesen_US
dc.subjectVirologyen_US
dc.subjectHIV-1-infected personsen_US
dc.subjectSurveillanceen_US
dc.subjectTherapyen_US
dc.subjectRecommendationsen_US
dc.subjectEpidemiologyen_US
dc.subjectUpdateen_US
dc.subject.meshAdulten_US
dc.subject.meshAnti-HIV agentsen_US
dc.subject.meshCD4 lymphocyte counten_US
dc.subject.meshDrug resistance, viralen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene expressionen_US
dc.subject.meshHIV infectionsen_US
dc.subject.meshHIV proteaseen_US
dc.subject.meshHIV protease inhibitorsen_US
dc.subject.meshHIV reverse transcriptaseen_US
dc.subject.meshHIV-1en_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMutationen_US
dc.subject.meshPrevalenceen_US
dc.subject.meshReverse transcriptase inhibitorsen_US
dc.subject.meshRNA, viralen_US
dc.subject.meshTurkeyen_US
dc.titleHIV-1 transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in Turkeyen_US
dc.typeArticleen_US
dc.identifier.wos000367335100005tr_TR
dc.identifier.scopus2-s2.0-84954092536tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları Anabilim Dalı.tr_TR
dc.identifier.startpage26tr_TR
dc.identifier.endpage31tr_TR
dc.identifier.volume32tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalAIDS Research and Human Retrovirusesen_US
dc.contributor.buuauthorAkalın, Halis-
dc.contributor.researcheridAAU-8952-2020en_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed26414663tr_TR
dc.subject.wosImmunologyen_US
dc.subject.wosInfectious diseasesen_US
dc.subject.wosVirologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ4 (Immunology)en_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid57207553671tr_TR
dc.subject.scopusPol Genes; Human Immunodeficiency Virus 1; Quasispeciesen_US
dc.subject.emtreeAntivirus agenten_US
dc.subject.emtreeNonnucleoside reverse transcriptase inhibitoren_US
dc.subject.emtreeRNA directed DNA polymerase inhibitoren_US
dc.subject.emtreeThymidine derivativeen_US
dc.subject.emtreeAnti human immunodeficiency virus agenten_US
dc.subject.emtreeHuman immunodeficiency virus proteinaseen_US
dc.subject.emtreeHuman immunodeficiency virus proteinase inhibitoren_US
dc.subject.emtreeRNA directed DNA polymeraseen_US
dc.subject.emtreeRNA directed DNA polymerase inhibitoren_US
dc.subject.emtreeVirus RNAen_US
dc.subject.emtreeAntiviral resistanceen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeCohort analysisen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman immunodeficiency virus 1en_US
dc.subject.emtreeHuman immunodeficiency virus 1 infectionen_US
dc.subject.emtreeHuman immunodeficiency virus infected patienten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreePrevalenceen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeVirus mutationen_US
dc.subject.emtreeVirus transmissionen_US
dc.subject.emtreeWorld health organizationen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAntiviral resistanceen_US
dc.subject.emtreeCD4 lymphocyte counten_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeGene expressionen_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeGrowth, development and agingen_US
dc.subject.emtreeHuman immunodeficiency virus 1en_US
dc.subject.emtreeHuman immunodeficiency virus infectionen_US
dc.subject.emtreeMetabolismen_US
dc.subject.emtreeMutationen_US
dc.subject.emtreeTransmissionen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Akalın_vd_2016.pdf149.1 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons